Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16437486rdf:typepubmed:Citationlld:pubmed
pubmed-article:16437486lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:16437486lifeskim:mentionsumls-concept:C0751651lld:lifeskim
pubmed-article:16437486pubmed:issue1lld:pubmed
pubmed-article:16437486pubmed:dateCreated2006-1-26lld:pubmed
pubmed-article:16437486pubmed:abstractTextMitochondrial respiratory chain disorders are the most prevalent group of inherited neurometabolic diseases. They present with central and peripheral neurological features usually in association with other organ involvement including the eye, the heart, the liver, and kidneys, diabetes mellitus and sensorineural deafness. Current treatment is largely supportive and the disorders progress relentlessly causing significant morbidity and premature death. Vitamin supplements, pharmacological agents and exercise therapy have been used in isolated cases and small clinical trials, but the efficacy of these interventions is unclear.lld:pubmed
pubmed-article:16437486pubmed:languageenglld:pubmed
pubmed-article:16437486pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16437486pubmed:citationSubsetIMlld:pubmed
pubmed-article:16437486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16437486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16437486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16437486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16437486pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16437486pubmed:statusMEDLINElld:pubmed
pubmed-article:16437486pubmed:issn1469-493Xlld:pubmed
pubmed-article:16437486pubmed:authorpubmed-author:MajamaaKKlld:pubmed
pubmed-article:16437486pubmed:authorpubmed-author:TurnbullDDlld:pubmed
pubmed-article:16437486pubmed:authorpubmed-author:ThorburnDDlld:pubmed
pubmed-article:16437486pubmed:authorpubmed-author:ChinneryPPlld:pubmed
pubmed-article:16437486pubmed:issnTypeElectroniclld:pubmed
pubmed-article:16437486pubmed:ownerNLMlld:pubmed
pubmed-article:16437486pubmed:authorsCompleteYlld:pubmed
pubmed-article:16437486pubmed:paginationCD004426lld:pubmed
pubmed-article:16437486pubmed:meshHeadingpubmed-meshheading:16437486...lld:pubmed
pubmed-article:16437486pubmed:meshHeadingpubmed-meshheading:16437486...lld:pubmed
pubmed-article:16437486pubmed:meshHeadingpubmed-meshheading:16437486...lld:pubmed
pubmed-article:16437486pubmed:meshHeadingpubmed-meshheading:16437486...lld:pubmed
pubmed-article:16437486pubmed:meshHeadingpubmed-meshheading:16437486...lld:pubmed
pubmed-article:16437486pubmed:meshHeadingpubmed-meshheading:16437486...lld:pubmed
pubmed-article:16437486pubmed:year2006lld:pubmed
pubmed-article:16437486pubmed:articleTitleTreatment for mitochondrial disorders.lld:pubmed
pubmed-article:16437486pubmed:affiliationUniversity of Newcastle upon Tyne, Department of Neurology, Medical School, Framlington Place, Newcastle Upon Tyne, UK, NE24 4HH. p.f.chinnery@ncl.ac.uklld:pubmed
pubmed-article:16437486pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16437486pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16437486lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16437486lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16437486lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16437486lld:pubmed